Dow Today: JPMorgan Chase (JPM) Lower

The Dow Jones Industrial Average ( ^DJI) is trading up 122 points (+0.8%) at 15,413 as of Thursday, Jul 11, 2013, 10:35 a.m. ET. During this time, 135.3 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 612 million. The NYSE advances/declines ratio sits at 2,589 issues advancing vs. 331 declining with 48 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Holding back the Dow today is JPMorgan Chase (NYSE: JPM), which is lagging the broader Dow index with a 22-cent decline (-0.4%) bringing the stock to $54.60. Volume for JPMorgan Chase currently sits at 7.1 million shares traded vs. an average daily trading volume of 22.7 million shares.

JPMorgan Chase has a market cap of $207.47 billion and is part of the financial sector and banking industry. Shares are up 24.7% year to date as of Wednesday's close. The stock's dividend yield sits at 2.8%.

JPMorgan Chase & Co., a financial holding company, provides various financial services worldwide.

TheStreet Ratings rates JPMorgan Chase as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing